Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Should You Buy The Dogs Of The FTSE For 2015? Royal Dutch Shell Plc, GlaxoSmithKline plc, Standard Chartered PLC, Direct Line Insurance Group PLC And Admiral Group plc

Royal Dutch Shell Plc (LON:RDSB), GlaxoSmithKline plc (LON:GSK), Standard Chartered PLC (LON:STAN), Direct Line Insurance Group PLC (LON:DLG) and Admiral Group plc (LON:ADM) could all beat the market in 2015.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This is the second part of my two-part series looking at the 10 FTSE 100 stocks that qualify for a UK version of the popular Dogs of the Dow high-yield investment strategy.

The Dogs strategy involves buying the 10 highest-yielding stocks in the index at the start of the year, and then selling them at the end of the year. In the US, the Dogs strategy has beaten the Dow in two of the last three years.

Here are the final five 2015 Dog stocks from the FTSE 100 (if you missed the first five stocks, you can catch up here):

Company

2015 prospective yield

Royal Dutch Shell (LSE: RDSB)

5.9%

GlaxoSmithKline (LSE: GSK)

5.9%

Standard Chartered (LSE: STAN)

6.0%

Direct Line Insurance Group (LSE: DLG)

7.4%

Admiral Group (LSE: ADM)

6.9%

Shell

No-one quite knows how the oil market will behave next year.

However, Shell should be able to afford to ride out the storm, thanks to its huge scale, large gas business and low debt levels.

Although cash flow could come under pressure next year, the firm’s forecast P/E of 9.8 suggests to me that Shell remains a safe income buy.

GlaxoSmithKline

Allegations of bribery and corruption, patent expiries, and falling profits.

It’s been a poor year for Glaxo, but this has left the UK’s largest pharmaceutical firm trading with a prospective yield of nearly 6% and a planned 82p per share capital return in 2015.

Glaxo remains in my portfolio, and on my buy list.

Standard Chartered

Shares in Asia-focused Standard Chartered have fallen by around 35% this year, amid a constant run of downgraded forecasts.

As a result, the bank’s shares trade on a 2015 forecast P/E of just 8.1, which prices in a lot of bad news, in my view. A prospective yield of around 5.9% should also reward patient investors.

Direct Line

Direct Line makes it into the Dogs of the FTSE thanks to a generous special dividend policy, which gives the firm’s shares a prospective yield of 7.4%, the highest in this group.

The fall in motor insurance premiums does seem to be slowing, so 2015 could be a reasonable year for Direct Line.

Admiral

As with Direct Line, it’s important to remember that these insurers’ generous yields are driven by special dividends, which are currently being paid every year, but may not be in the future.

That aside, Admiral’s 2015 forecast P/E of 14.2 reflects the fact that earnings per share are expected to fall by around 8% next year, raising the risk that dividend growth could also stall.

Roland Head owns shares in Royal Dutch Shell and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

This cheap FTSE 100 stock outperformed Barclays, IAG, and Games Workshop shares in 2025 but no one’s talking about it

This FTSE stock has delivered fantastic gains in 2025, outperforming a lot of more popular shares. Yet going into 2026,…

Read more »

Close-up of British bank notes
Investing Articles

100 Lloyds shares cost £55 in January. Here’s what they’re worth now!

How well have Lloyds shares done in 2025? Very well is the answer, as our writer explains. But they still…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

How much do you need in an ISA to target £2,000 a month of passive income

Our writer explores a passive income strategy that involves the most boring FTSE 100 share. But when it comes to…

Read more »

Investing Articles

£5,000 invested in a FTSE 250 index tracker at the start of 2025 is now worth…

Despite underperforming the FTSE 100, the FTSE 250 has been the place to find some of the UK’s top growth…

Read more »

Investing Articles

2 of the most compelling passive income strategies for 2026

Selling 'covered calls' could generate cash for investors in a stock market crash. But that’s not Stephen Wright’s top passive…

Read more »

Investing Articles

Up 136%, is this under-the-radar growth stock the UK’s hottest opportunity for 2026?

Amcomri has only been on the market a year, but it’s been one of the UK’s top growth stocks and…

Read more »

Senior couple are walking their dog through a public park in Autumn.
Investing Articles

If a 30-year-old puts £500 a month in a SIPP, by retirement, they’d have…

Worried about not having enough money to retire on? Regularly investing in a Self-Invested Personal Pension (SIPP) may be worth…

Read more »

Investing Articles

Should I sell my Rolls-Royce shares in 2026?

This writer is wondering what to do with his Rolls-Royce shares after an incredible three-year run. Is it finally time…

Read more »